NEW YORK (GenomeWeb) – BASF announced it has reached a non-exclusive, worldwide licensing agreement with the Broad Institute for CRISPR/Cas9 genome editing in ag-bio and industrial applications.

"We are eager to see the new ways it will augment our research and improve multiple products for agriculture as well as numerous industrial applications," Peter Eckes, president of BASF bioscience research, said in a statement.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.